NL
RXRX icon

NVWM LLC’s Recursion Pharmaceuticals RXRX Stock Holding History

NVWM LLC’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$525 Hold
171
– – ﹤0.01% 648
2025
Q4 		$699 Hold
171
– – ﹤0.01% 615
2025
Q3 		$834 Hold
171
– – ﹤0.01% 551
2025
Q2 		$865 Hold
171
– – ﹤0.01% 536
2025
Q1 		$905 Hold
171
– – ﹤0.01% 504
2024
Q4 		$1.16K Hold
171
– – ﹤0.01% 446
2024
Q3 		$1.13K Hold
171
– – ﹤0.01% 451
2024
Q2 		$1.28K Hold
171
– – ﹤0.01% 406
2024
Q1 		$1.71K Buy
171
+48
+39% +$535 ﹤0.01% 366
2023
Q4 		$1.21K Hold
123
– – ﹤0.01% 373
2023
Q3 		$941 Buy
+123
New +$1.23K ﹤0.01% 399

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

NVWM LLC's RXRX Position: Q1 2026 in Review

NVWM LLC held its Recursion Pharmaceuticals (RXRX) position steady in Q1 2026 at 171 shares worth $525. The position accounts for ﹤0.01% of the portfolio, ranked #648.

NVWM LLC first reported a position in RXRX in Q3 2023 and has held it in 11 quarters since. The position peaked at $1.71K in Q1 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • NVWM LLC held 171 shares of Recursion Pharmaceuticals worth $525 as of Q1 2026.
  • NVWM LLC left its Recursion Pharmaceuticals share count unchanged in Q1 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of NVWM LLC's portfolio in Q1 2026, its #648 holding.
  • NVWM LLC first reported a position in Recursion Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
  • NVWM LLC's Recursion Pharmaceuticals position peaked at $1.71K in Q1 2024.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on NVWM LLC's 13F filing for Q1 2026, filed 27 Apr 2026.